GlassScriptPhysician profile
Paul D Koerner
NPI 1023072485
$2,741.72
in general payments reported to CMS, 2019-2025
45 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $250 · 2021: $227 · 2022: $313 · 2023: $570 · 2024: $525 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $272.78 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $249.20 | 2019-2025 | |
| Janssen Biotech, INC. | $210.10 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Amgen INC. | $189.92 | 2019-2023 | Kyprolis |
| Incyte Corporation | $135.14 | 2021-2024 | Monjuvi, Pemazyre, Jakafi |
| Abbvie INC. | $134.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $121.28 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.50 | 2019-2025 | Ninlaro, Iclusig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.45 | 2019-2025 | |
| Taiho Oncology, INC. | $79.46 | 2019-2025 | |
| Boston Scientific Corporation | $70.14 | 2019-2025 | Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $62.28 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $60.81 | 2023-2024 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $60.68 | 2022-2023 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $60.49 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Koerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.